

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Omaveloxolone for treating Friedreich's ataxia in people 16 years and over [ID6423]

Final Stakeholder List

Provisional Consultees		Provisional Commentators (no right to submit or appeal)
Co	ompany	General
•	Biogen (omaveloxolone)	All Wales Inherited Metabolic Disease Service
Patient/carer groups		All Wales Therapeutics and Toxicology
•	Ataxia UK	Centre
•	Beacon	Allied Health Professionals Federation
•	Brain and Spine Foundation	Board of Community Health Councils in
•	Brain Charity	Wales
•	Cardiomyopathy UK	British National Formulary
•	Diabetes UK	Care Quality Commission
•	Gene People	Department of Health - Northern Ireland
•	Genetic Alliance UK	Healthcare Improvement Scotland
•	Neurological Alliance	Medicines and Healthcare products
•	Scoliosis Support & Research	Regulatory Agency
•	South Asian Health Foundation	National Association of Primary Care
•	Specialised Healthcare Alliance	National Pharmacy Association
	•	Neurological Alliance of Scotland
Healthcare professional groups		NHS Confederation
•	Association of British Neurologists	Scottish Medicines Consortium
•	British Association of Neuroscience	Wales Neurological Alliance
	Nurses	Welsh Government
•	British Geriatrics Society	Welsh Health Specialised Services
•	British Neuropathological Society	Committee
•	British Society for Blood and Marrow	
	Transplantation	Comparator companies
•	British Society of Rehabilitation	None
	Medicine	
•	Chartered Society of Physiotherapy	Relevant research groups
•	Institute of Neurology	Brain Research UK
•	National Neurosciences Advisory	Cochrane Multiple Sclerosis and Rare
	Group	Diseases of the Central Nervous
•	Primary Care and Community	System Group
	Neurology Society	Genomics England MDC Official Trial III if
•	Royal College of General Practitioners	MRC Clinical Trials Unit
•	Royal College of Nursing	 National Hospital for Neurology and Neurosurgery

Final stakeholder list for the evaluation of omaveloxolone for treating Friedreich's ataxia in people 16 years and over [ID6423]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Occupational Therapists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England NHS Genomic Network of Excellence NHS Genomic Medicine Service 	 National Institute for Health Research Oxford Ataxia Centre Oxford-Harrington Rare Disease Centre Paediatric Ataxia Centre, National Hospitals for Neurology and Neurosurgery Sheffield Children's Centre The London Ataxia Centre, National Hospitals for Neurology and Neurosurgery The Sheffield Ataxia Centre, Department of Neurology, Royal Hallamshire Hospital UCL Queen Square Institute of Neurology Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of omaveloxolone for treating Friedreich's ataxia in people 16 years and over [ID6423]

Issue date: October 2024





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.